Clinical Trial

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 20, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed with high-dose Furmonertinib plus bevacizumab for EGFR-mutant non-small cell lung cancer patients with leptomeningeal metastases after resistance to third-generation EGFR-TKIs.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-01; most recent amendment 2024-09-17.
Trial Details
NCT Number NCT06537297
Lead Sponsor Hunan Province Tumor Hospital
Conditions Non-small Cell Lung Cancer
Enrollment 30 participants
Start Date 2024-09-30
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-20